Human BioSystems to Expand Into Larger Research Facility

Palo Alto, CA – September 26, 2006 - (OTCBB:HBSC) Human BioSystems (“HBS” or “Company”) announced today that the Company signed a lease to move from its current research facility in Vicksburg, Michigan to a larger facility in the same city.

Dr. Luis Toledo, Chief Medical Officer for HBS said that “All of our organ preservation research studies were done here at our present facility, but we are looking forward to moving to larger facilities to accommodate additional equipment that will be needed to conduct our freezing technology tests on Islet cells and to continue work on organs.”

HBS signed a five year lease to commence occupancy in December of 2006, after improvements to the space are made to suit the Company’s laboratory and office needs.

Human BioSystems is a developer of preservation platforms for organs, platelets and other biomaterials.   The Company, which is headquartered in Palo Alto, California has research facilities in Michigan.

Contact:

Human BioSystems               
Harry Masuda                   
CEO                       
(650) 323-0943                   
This email address is being protected from spam bots, you need Javascript enabled to view it            

Investor  Relations
Yes International
Rich Kaiser
(800) 631-8127
This email address is being protected from spam bots, you need Javascript enabled to view it

Investor Relations
Concept Communications, LLC
James D. Caldwell
(727) 447-0514
This email address is being protected from spam bots, you need Javascript enabled to view it


Certain statements contained herein are “forward-looking'' statements (as such term is defined in the Private Securities Litigation Reform Act of 1995). Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, results from ongoing research and development as well as clinical studies, failure to obtain regulatory approval for the Company’s products, if required, failure to develop a product based on the Company’s technology, failure of any such products to compete effectively with existing products, the inability to find a strategic partner or to consummate a relationship with a potential strategic partner on acceptable terms, and other factors discussed in filings made by the Company with the Securities and Exchange Commission